<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Dyne Therapeutics - FORCE Platform | DMD Exon 44 Analysis</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://cdn.jsdelivr.net/npm/chart.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700&display=swap" rel="stylesheet">
    <style>
        * { font-family: 'Inter', sans-serif; }
        .tab-content { display: none; }
        .tab-content.active { display: block; }
        .tab-button.active { 
            border-bottom-color: rgb(99 102 241); 
            color: rgb(99 102 241);
        }
    </style>
</head>
<body class="bg-gray-50 text-gray-900">
    <!-- Header -->
       <header class="bg-gradient-to-r from-emerald-50 via-blue-50 to-purple-50 relative shadow-lg">
        <!-- Glassmorphism overlay -->
        <div class="absolute inset-0 bg-white/60 backdrop-blur-md border-b border-white/20"></div>
        
        <div class="container mx-auto relative z-10">
            <nav class="flex justify-between items-center px-4 py-4">
                <!-- Logo/Brand section -->
                <div class="flex items-center space-x-3">
                    <div class="relative">
                        <img src="leaf.png" alt="Leaf Intelligence" class="h-14 w-14 object-contain">
                        <!-- Subtle glow effect -->
                        <div class="absolute inset-0 bg-gradient-to-r from-emerald-400 to-cyan-400 opacity-20 blur-lg rounded-full"></div>
                    </div>
                    <div class="ml-3">
                        <span class="text-xl font-bold bg-gradient-to-r from-emerald-600 via-blue-600 to-purple-600 bg-clip-text text-transparent">
                            Leaf Intelligence
                        </span>
                        <div class="text-xs text-gray-600 font-medium tracking-wide">AI Research Platform</div>
                    </div>
                </div>

                <!-- Competitive Intelligence -->
                <div class="relative bg-white/40 backdrop-blur-sm border border-white/30 text-gray-700 transition-all duration-300 flex items-center text-sm font-medium px-4 py-2 rounded-lg hover:bg-white/60 hover:border-blue-200/50 hover:shadow-lg">
                    <span class="bg-gradient-to-r from-emerald-600 via-blue-600 to-purple-600 bg-clip-text text-transparent">
                        Competitive intelligence
                    </span>
                </div>
            </nav>
        </div>
    </header>
    <header class="bg-white border-b border-gray-200">
        <div class="max-w-7xl mx-auto px-4 sm:px-6 lg:px-8 py-6">
            <div class="flex items-center justify-between">
                <div>
                    <h1 class="text-3xl font-bold text-gray-900">Dyne Therapeutics</h1>
                    <p class="text-lg text-gray-600 mt-1">FORCE™ Platform - Future Competitive Threat</p>
                </div>
                <button onclick="window.close()" class="px-4 py-2 bg-gray-100 hover:bg-gray-200 rounded-lg transition-colors">
                    Close
                </button>
            </div>
            
            <!-- Threat Assessment -->
            <div class="bg-gradient-to-r from-green-50 to-green-100 rounded-xl p-6 mt-6">
                <div class="flex items-center justify-between">
                    <div>
                        <h3 class="text-lg font-semibold text-green-900">Threat Level: Low (#4) - Currently</h3>
                        <p class="text-green-700 mt-1">Preclinical exon 44 program, focus on other targets</p>
                    </div>
                    <div class="text-4xl">🟡</div>
                </div>
            </div>
        </div>
    </header>

    <!-- Navigation Tabs -->
    <nav class="bg-white border-b border-gray-200 sticky top-0 z-10">
        <div class="max-w-7xl mx-auto px-4 sm:px-6 lg:px-8">
            <div class="flex space-x-8">
                <button onclick="showTab('overview')" class="tab-button py-4 px-1 border-b-2 border-transparent font-medium text-sm text-gray-500 hover:text-gray-700">
                    Overview
                </button>
                <button onclick="showTab('clinical')" class="tab-button py-4 px-1 border-b-2 border-transparent font-medium text-sm text-gray-500 hover:text-gray-700">
                    Clinical Programs
                </button>
                <button onclick="showTab('patents')" class="tab-button active py-4 px-1 border-b-2 font-medium text-sm">
                    Patent Portfolio
                </button>
                <button onclick="showTab('financial')" class="tab-button py-4 px-1 border-b-2 border-transparent font-medium text-sm text-gray-500 hover:text-gray-700">
                    Financial Data
                </button>
                <button onclick="showTab('platform')" class="tab-button py-4 px-1 border-b-2 border-transparent font-medium text-sm text-gray-500 hover:text-gray-700">
                    FORCE Platform
                </button>
            </div>
        </div>
    </nav>

    <!-- Main Content -->
    <main class="max-w-7xl mx-auto px-4 sm:px-6 lg:px-8 py-8">
        <!-- Patents Tab (Continued) -->
        <div id="patents" class="tab-content active">
            <div class="bg-white rounded-lg shadow-sm border border-gray-200 p-6 mb-6">
                <h2 class="text-xl font-semibold mb-4">Patent Portfolio Analysis</h2>
                
                <div class="mb-6">
                    <h3 class="font-semibold text-red-900 mb-3">High Proximity Patents (Score: 80-100)</h3>
                    <div class="space-y-3">
                        <div class="bg-red-50 border border-red-200 rounded-lg p-4">
                            <div class="flex items-start justify-between">
                                <div>
                                    <h4 class="font-medium text-red-900">US12329825B1</h4>
                                    <p class="text-sm text-gray-600 mt-1">PMO conjugated to anti-TfR antibody targeting exon 44. DAR 1-5.</p>
                                </div>
                                <span class="px-2 py-1 bg-red-100 text-red-700 rounded-full text-xs font-semibold">Score: 95</span>
                            </div>
                        </div>
                        
                        <div class="bg-red-50 border border-red-200 rounded-lg p-4">
                            <div class="flex items-start justify-between">
                                <div>
                                    <h4 class="font-medium text-red-900">US12325753B2</h4>
                                    <p class="text-sm text-gray-600 mt-1">PMO-anti-TfR antibody complex for muscular dystrophy</p>
                                </div>
                                <span class="px-2 py-1 bg-red-100 text-red-700 rounded-full text-xs font-semibold">Score: 90</span>
                            </div>
                        </div>
                        
                        <div class="bg-red-50 border border-red-200 rounded-lg p-4">
                            <div class="flex items-start justify-between">
                                <div>
                                    <h4 class="font-medium text-red-900">US12173079B2</h4>
                                    <p class="text-sm text-gray-600 mt-1">Complexes with anti-TfR antibody and PMO targeting muscle diseases</p>
                                </div>
                                <span class="px-2 py-1 bg-red-100 text-red-700 rounded-full text-xs font-semibold">Score: 85</span>
                            </div>
                        </div>
                        
                        <div class="bg-red-50 border border-red-200 rounded-lg p-4">
                            <div class="flex items-start justify-between">
                                <div>
                                    <h4 class="font-medium text-red-900">US12263225B2</h4>
                                    <p class="text-sm text-gray-600 mt-1">Similar conjugate platform targeting exon 51 of DMD, including valine-citrulline linkers and DARs of 1-3</p>
                                </div>
                                <span class="px-2 py-1 bg-red-100 text-red-700 rounded-full text-xs font-semibold">Score: 85</span>
                            </div>
                        </div>
                    </div>
                </div>

                <div>
                    <h3 class="font-semibold text-orange-900 mb-3">Medium Proximity Patents (Score: 30-60)</h3>
                    <div class="bg-orange-50 border border-orange-200 rounded-lg p-4">
                        <p class="text-sm text-gray-600">
                            9 additional medium proximity patents covering production methods, antibody variants, 
                            and other DMD-related exons or disease types:
                        </p>
                        <p class="text-xs text-gray-500 mt-2">
                            US12144868B2, US11248056B1, US11795234B2, US11795233B2, US11787869B2, 
                            US12128109B2, US12239717B2, US11844843B2, US12018087B2
                        </p>
                    </div>
                </div>
            </div>
        </div>

        <!-- Financial Tab -->
        <div id="financial" class="tab-content">
            <div class="bg-white rounded-lg shadow-sm border border-gray-200 p-6 mb-6">
                <h2 class="text-xl font-semibold mb-4">Financial Strength & Investment</h2>
                
                <div class="grid grid-cols-1 md:grid-cols-3 gap-6 mb-6">
                    <div class="bg-green-50 rounded-lg p-6">
                        <p class="text-sm text-gray-600">Cash Position</p>
                        <p class="text-3xl font-bold text-green-800">$678-779M</p>
                        <p class="text-sm text-gray-500 mt-1">As of mid-2025</p>
                    </div>
                    <div class="bg-blue-50 rounded-lg p-6">
                        <p class="text-sm text-gray-600">Recent Raises</p>
                        <p class="text-3xl font-bold text-blue-800">$574M</p>
                        <p class="text-sm text-gray-500 mt-1">2024-2025</p>
                    </div>
                    <div class="bg-purple-50 rounded-lg p-6">
                        <p class="text-sm text-gray-600">Runway</p>
                        <p class="text-3xl font-bold text-purple-800">Mid-2026</p>
                        <p class="text-sm text-gray-500 mt-1">Operational funding</p>
                    </div>
                </div>

                <h3 class="font-semibold mb-3">Capital Raises & Milestones</h3>
                <div class="overflow-x-auto">
                    <table class="w-full text-sm">
                        <thead>
                            <tr class="border-b">
                                <th class="text-left py-2">Period</th>
                                <th class="text-right py-2">Amount Raised</th>
                                <th class="text-left py-2">Key Development</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr class="border-b">
                                <td class="py-2">Q2 2024</td>
                                <td class="text-right font-semibold">$374M</td>
                                <td>Strong investor confidence post-DYNE-251 data</td>
                            </tr>
                            <tr class="border-b">
                                <td class="py-2">Mid-2025</td>
                                <td class="text-right font-semibold">$200M</td>
                                <td>Minimal dilution, strategic raise</td>
                            </tr>
                            <tr class="border-b bg-yellow-50">
                                <td class="py-2 font-semibold">Total</td>
                                <td class="text-right font-semibold">$574M</td>
                                <td>2024-2025 period</td>
                            </tr>
                        </tbody>
                    </table>
                </div>

                <div class="mt-6 bg-yellow-50 rounded-lg p-6">
                    <h3 class="font-semibold text-yellow-900 mb-3">Investment Highlights</h3>
                    <ul class="space-y-2 text-sm">
                        <li>• Ability to fund multiple programs in parallel</li>
                        <li>• Strategic flexibility for exon 44 entry if desired</li>
                        <li>• Strong balance sheet despite executive departures</li>
                        <li>• Continued investor confidence in FORCE platform</li>
                    </ul>
                </div>

                <div class="mt-6 bg-red-50 rounded-lg p-4">
                    <p class="text-sm text-red-900">
                        <strong>Note:</strong> September 2024 executive departures (CMO, CCO, CBO) created temporary 
                        uncertainty but core operations remain strong.
                    </p>
                </div>
            </div>
        </div>

        <!-- FORCE Platform Tab -->
        <div id="platform" class="tab-content">
            <div class="bg-white rounded-lg shadow-sm border border-gray-200 p-6 mb-6">
                <h2 class="text-xl font-semibold mb-4">FORCE™ Platform Technology</h2>
                
                <div class="bg-purple-50 rounded-lg p-6 mb-6">
                    <h3 class="font-semibold text-purple-900 mb-3">Platform Capabilities</h3>
                    <ul class="space-y-2">
                        <li class="flex items-start">
                            <span class="text-purple-600 mr-2">•</span>
                            <span>Fab antibody fragment conjugated to oligonucleotides</span>
                        </li>
                        <li class="flex items-start">
                            <span class="text-purple-600 mr-2">•</span>
                            <span>TfR1 targeting for muscle-specific delivery</span>
                        </li>
                        <li class="flex items-start">
                            <span class="text-purple-600 mr-2">•</span>
                            <span>Modular design enables multiple disease targets</span>
                        </li>
                        <li class="flex items-start">
                            <span class="text-purple-600 mr-2">•</span>
                            <span>Demonstrated safety in 54 participants (DELIVER trial)</span>
                        </li>
                    </ul>
                </div>

                <div class="grid grid-cols-1 md:grid-cols-2 gap-6 mb-6">
                    <div class="bg-green-50 rounded-lg p-4">
                        <h4 class="font-medium text-green-900 mb-2">Platform Advantages</h4>
                        <ul class="text-sm space-y-1">
                            <li>• Proven clinical efficacy (8.72% dystrophin)</li>
                            <li>• Good safety profile</li>
                            <li>• Platform scalability across exons</li>
                            <li>• Established manufacturing</li>
                        </ul>
                    </div>
                    <div class="bg-yellow-50 rounded-lg p-4">
                        <h4 class="font-medium text-yellow-900 mb-2">vs AOC Platform</h4>
                        <ul class="text-sm space-y-1">
                            <li>• Lower dystrophin levels (8.72% vs 25-58%)</li>
                            <li>• Less clinical data available</li>
                            <li>• Significantly behind in exon 44</li>
                            <li>• No exon 44-specific data</li>
                        </ul>
                    </div>
                </div>

                <div class="bg-gray-50 rounded-lg p-6">
                    <h3 class="font-semibold mb-3">Platform Applications</h3>
                    <div class="grid grid-cols-2 md:grid-cols-4 gap-4">
                        <div class="text-center">
                            <p class="font-semibold">DMD Exon 51</p>
                            <p class="text-xs text-gray-600">Phase 2/3</p>
                        </div>
                        <div class="text-center">
                            <p class="font-semibold">DMD Exon 44</p>
                            <p class="text-xs text-gray-600">Preclinical</p>
                        </div>
                        <div class="text-center">
                            <p class="font-semibold">DM1</p>
                            <p class="text-xs text-gray-600">Phase 1/2</p>
                        </div>
                        <div class="text-center">
                            <p class="font-semibold">FSHD</p>
                            <p class="text-xs text-gray-600">Multiple programs</p>
                        </div>
                    </div>
                </div>
            </div>
        </div>

        <!-- Overview Tab (Hidden by default) -->
        <div id="overview" class="tab-content">
            <div class="bg-white rounded-lg shadow-sm border border-gray-200 p-6 mb-6">
                <h2 class="text-xl font-semibold mb-4">Strategic Threat Assessment</h2>
                
                <div class="grid grid-cols-1 md:grid-cols-2 gap-6">
                    <div>
                        <h3 class="font-semibold text-gray-900 mb-3">Why They're Less of a Threat (Now)</h3>
                        <ul class="space-y-2 text-sm text-gray-600">
                            <li class="flex items-start">
                                <span class="text-yellow-600 mr-2">❌</span>
                                <span>No active exon 44 program in clinic</span>
                            </li>
                            <li class="flex items-start">
                                <span class="text-yellow-600 mr-2">❌</span>
                                <span>Focused on DYNE-251 (exon 51) and FSHD</span>
                            </li>
                            <li class="flex items-start">
                                <span class="text-yellow-600 mr-2">❌</span>
                                <span>3+ years behind AOC-1044</span>
                            </li>
                            <li class="flex items-start">
                                <span class="text-yellow-600 mr-2">❌</span>
                                <span>No regulatory designations for exon 44</span>
                            </li>
                            <li class="flex items-start">
                                <span class="text-yellow-600 mr-2">❌</span>
                                <span>Executive departures in September 2024</span>
                            </li>
                        </ul>
                    </div>
                    
                    <div>
                        <h3 class="font-semibold text-gray-900 mb-3">Future Risk Factors</h3>
                        <ul class="space-y-2 text-sm text-gray-600">
                            <li class="flex items-start">
                                <span class="text-green-600 mr-2">✓</span>
                                <span>Strong platform with 8.72% dystrophin (DYNE-251)</span>
                            </li>
                            <li class="flex items-start">
                                <span class="text-green-600 mr-2">✓</span>
                                <span>$670M+ cash position enables aggressive development</span>
                            </li>
                            <li class="flex items-start">
                                <span class="text-green-600 mr-2">✓</span>
                                <span>Multi-exon strategy could leverage learnings</span>
                            </li>
                            <li class="flex items-start">
                                <span class="text-green-600 mr-2">✓</span>
                                <span>4 high-proximity patents for exon 44</span>
                            </li>
                            <li class="flex items-start">
                                <span class="text-green-600 mr-2">✓</span>
                                <span>Could enter later and leapfrog if AOC-1044 delayed</span>
                            </li>
                        </ul>
                    </div>
                </div>
            </div>

            <div class="bg-white rounded-lg shadow-sm border border-gray-200 p-6">
                <h3 class="font-semibold mb-3">Key Competitive Metrics</h3>
                <div class="grid grid-cols-2 md:grid-cols-4 gap-4">
                    <div class="text-center p-4 bg-gray-50 rounded-lg">
                        <p class="text-2xl font-bold text-green-600">Preclinical</p>
                        <p class="text-xs text-gray-600">Exon 44 Stage</p>
                    </div>
                    <div class="text-center p-4 bg-gray-50 rounded-lg">
                        <p class="text-2xl font-bold text-blue-600">8.72%</p>
                        <p class="text-xs text-gray-600">DYNE-251 Dystrophin</p>
                    </div>
                    <div class="text-center p-4 bg-gray-50 rounded-lg">
                        <p class="text-2xl font-bold text-purple-600">$678-779M</p>
                        <p class="text-xs text-gray-600">Cash Position</p>
                    </div>
                    <div class="text-center p-4 bg-gray-50 rounded-lg">
                        <p class="text-2xl font-bold text-red-600">4</p>
                        <p class="text-xs text-gray-600">High Proximity Patents</p>
                    </div>
                </div>
            </div>
        </div>

        <!-- Clinical Programs Tab (Hidden by default) -->
        <div id="clinical" class="tab-content">
            <div class="bg-white rounded-lg shadow-sm border border-gray-200 p-6 mb-6">
                <h2 class="text-xl font-semibold mb-4">Clinical Pipeline</h2>
                
                <div class="bg-blue-50 rounded-lg p-6 mb-6">
                    <h3 class="font-semibold text-blue-900 mb-3">DYNE-251 (Exon 51) - Lead Program</h3>
                    <div class="grid grid-cols-2 gap-4">
                        <div>
                            <p class="text-sm text-gray-600">Dystrophin Expression</p>
                            <p class="text-3xl font-bold text-blue-900">8.72%</p>
                            <p class="text-sm text-gray-500 mt-1">Exceeds eteplirsen</p>
                        </div>
                        <div>
                            <p class="text-sm text-gray-600">Phase</p>
                            <p class="text-3xl font-bold text-blue-900">Registrational</p>
                            <p class="text-sm text-gray-500 mt-1">20 mg/kg Q4W</p>
                        </div>
                    </div>
                    
                    <div class="mt-4">
                        <h4 class="font-medium mb-2">DELIVER Trial Data</h4>
                        <ul class="text-sm text-gray-600 space-y-1">
                            <li>• 54 participants received 970 doses</li>
                            <li>• ~77 patient-years exposure</li>
                            <li>• 3 serious AEs at high dose (40 mg/kg)</li>
                            <li>• No persistent anemia, thrombocytopenia, or kidney issues</li>
                        </ul>
                    </div>
                </div>

                <h3 class="font-semibold mb-3">Program Status</h3>
                <div class="space-y-4">
                    <div class="border border-gray-200 rounded-lg p-4">
                        <div class="flex items-center justify-between">
                            <div>
                                <h4 class="font-medium text-gray-900">Exon 44 Program</h4>
                                <p class="text-sm text-gray-600 mt-1">Status: Preclinical development</p>
                            </div>
                            <span class="px-3 py-1 bg-green-100 text-green-700 rounded-full text-sm">Early Stage</span>
                        </div>
                    </div>
                    
                    <div class="border border-gray-200 rounded-lg p-4">
                        <div class="flex items-center justify-between">
                            <div>
                                <h4 class="font-medium text-gray-900">DM1 Program</h4>
                                <p class="text-sm text-gray-600 mt-1">ACHIEVE trial ongoing</p>
                            </div>
                            <span class="px-3 py-1 bg-purple-100 text-purple-700 rounded-full text-sm">Phase 1/2</span>
                        </div>
                    </div>
                    
                    <div class="border border-gray-200 rounded-lg p-4">
                        <div class="flex items-center justify-between">
                            <div>
                                <h4 class="font-medium text-gray-900">FSHD Program</h4>
                                <p class="text-sm text-gray-600 mt-1">Multiple programs in development</p>
                            </div>
                            <span class="px-3 py-1 bg-blue-100 text-blue-700 rounded-full text-sm">Various Stages</span>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </main>

    <!-- Footer -->
    <footer class="bg-gray-100 py-4 mt-12">
        <div class="max-w-7xl mx-auto px-4 sm:px-6 lg:px-8">
            <p class="text-xs text-gray-600 text-center">
                Last updated: July 28, 2025 | Data sources: Clinical trial registrations, investor presentations, SEC filings, press releases
            </p>
        </div>
    </footer>

    <script>
        // Tab functionality
        function showTab(tabName) {
            // Hide all tabs
            document.querySelectorAll('.tab-content').forEach(tab => {
                tab.classList.remove('active');
            });
            
            // Remove active class from all buttons
            document.querySelectorAll('.tab-button').forEach(button => {
                button.classList.remove('active', 'text-indigo-600', 'border-indigo-500');
                button.classList.add('text-gray-500', 'border-transparent');
            });
            
            // Show selected tab
            document.getElementById(tabName).classList.add('active');
            
            // Set active button
            event.target.classList.remove('text-gray-500', 'border-transparent');
            event.target.classList.add('active', 'text-indigo-600', 'border-indigo-500');
        }
    </script>
</body>
</html>